




RealRate

PHARMACEUTICAL 2021

Traverse Therapeutics Inc.
Rank 260 of 402





RealRate

PHARMACEUTICAL 2021

Traverse Therapeutics Inc. Rank 260 of 402



The relative strengths and weaknesses of Traverse Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Traverse Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 35% points. The greatest weakness of Traverse Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 93% points.

The company's Economic Capital Ratio, given in the ranking table, is 38%, being 8.9% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	410,407
Cost of Goods Sold	6,126
Intangible Assets	154,125
Liabilities, Current	92,660
Liabilities, Non-Current	40,527
Other Assets	33,489
Other Compr. Net Income	-1,628
Other Expenses	81,427
Other Liabilities	263,039
Other Net Income	-12,627
Other Revenues	198,321
Property and Equipment	9,418
Research and Development	131,773
Selling, General and Administrative Expense	135,799

Output Variable	Value in 1000 USD
Assets	607,439
Liabilities	396,226
Expenses	355,125
Revenues	198,321
Stockholders Equity	211,213
Net Income	-169,431
Comprehensive Net Income	-170,245
Economic Capital Ratio	38%